KLK3 and posterior cortical atrophy: Despite the emergence of various new technologies and endocrine therapies for late-stage PCa, the mortality rate of PCa continues to rise.[4] Therefore, although prostate-specific antigen (PSA) levels have been widely used in the diagnosis of PCa,[5,6] there is still a need to identify new serum markers for early detection of PCa, which would significantly improve patient treatment and prognosis.